Proteoform-Specific Drug Interactions in Native Cell Membranes: Advances and Implications

Study Background and Research Question

Human biology is characterized by remarkable protein diversity, where alternative splicing and post-translational modifications (PTMs) generate a vast array of unique proteoforms from a limited set of protein-coding genes. This diversity, now estimated to encompass hundreds of thousands of distinct proteoforms, plays a crucial role in physiological processes and disease states. Understanding how these proteoforms interact with drugs, particularly in their native cellular environment, is a major challenge for drug discovery. Traditional cell-based assays and peptide-centric mass spectrometry approaches often fail to resolve the effects of individual PTMs on protein–ligand interactions. The key research question addressed by the study (DOI: 10.1038/s41557-024-01711-w) is how to directly characterize proteoform-specific interactions within native membranes and link these molecular features to drug targeting and potential off-target effects.

Key Innovation from the Reference Study

The central innovation of Lutomski et al. is the application of native top-down mass spectrometry (MS) to directly extract, sequence, and characterize membrane protein proteoforms and their complexes from unmodified cell membranes. By deploying infrared irradiation within a mass spectrometer, the researchers were able to release intact protein complexes—including G protein-coupled receptors (GPCRs) and their effectors—from native retinal rod disc membranes. This approach enables the preservation of native protein modifications and interactions, crucial for understanding the molecular determinants of drug specificity and off-target binding. Notably, the study demonstrates the ability to localize labile lipid modifications, such as palmitoylations, and map their influence on protein assembly and membrane association. This represents a substantial advance over prior methods, which required detergents or artificial mimetics and often lost critical information about native PTMs and their functional relevance.

Methods and Experimental Design Insights

The study employed an optimized workflow combining native mass spectrometry with infrared multiphoton dissociation (IRMPD) to sequence intact proteoforms and their complexes. The research focused on rhodopsin, an archetypal GPCR, and its signaling partners within native retinal membranes. Key steps included:

• Direct liberation of membrane proteins and complexes from rod disc membranes using IR irradiation, preserving native lipid and PTM states.
• Isolation of specific protein complexes—such as rhodopsin–G protein assemblies—followed by top-down sequencing to resolve proteoform-specific features.
• Systematic characterization of labile modifications (e.g., palmitoylation) and their spatial localization on proteins, enabling functional annotation of PTMs in native assemblies.
• Assessment of drug–protein interactions: The team investigated off-target binding of two clinically relevant cGMP-specific phosphodiesterase type 5 (PDE5) inhibitors, sildenafil and vardenafil, with retinal PDE6 and G protein proteoforms.

This experimental strategy overcomes the limitations of both bottom-up proteomics (which typically lose PTM context) and prior native MS approaches (which relied on artificial membrane mimetics), allowing for direct correlation of proteoform modifications with drug binding within a natural membrane environment.

Core Findings and Why They Matter

The study's most consequential findings relate to the demonstration that proteoform-specific interactions—especially those influenced by PTMs—determine both the efficacy and off-target reactivity of drugs. Among the key results:

• Proteoform-resolved interaction mapping: The team successfully sequenced individual rhodopsin proteoforms, identifying labile palmitoylations and lipid modifications on G proteins that modulate their assembly and membrane affinity.
• Drug binding specificity: They observed differential off-target binding of PDE5 inhibitors to retinal PDE6, with distinct interaction preferences for particular proteoforms, especially those with lipidation. This mechanistic insight helps to explain reported vision-related side effects associated with drugs such as sildenafil and vardenafil (reference study).
• Functional consequences of PTMs: Discovery of a Gβγ proteoform that, upon lipidation, loses membrane association, highlighting how single PTM events can fundamentally alter protein localization and complex assembly.

These findings underscore the importance of analyzing drug–protein interactions at the proteoform level—crucial for designing safer, more selective therapeutics and for understanding the molecular underpinnings of adverse drug reactions in tissues such as the retina.

Comparison with Existing Internal Articles

Several recent internal articles have explored related themes in proteoform-specific drug action and experimental approaches:

• The article "Proteoform-Specific Drug Interactions in Native Cell Signaling" contextualizes the reference study's technical advance, emphasizing how native top-down MS enables unprecedented insight into complex membrane protein–ligand dynamics, especially for compounds relevant to vascular research.
• "Sildenafil Citrate: Precision PDE5 Inhibition for Proteoform-Specific Research" highlights the utility of cGMP-specific phosphodiesterase type 5 inhibitors in dissecting vascular signaling pathways and apoptosis regulation via cGMP signaling, drawing on evidence that selective PDE5 inhibitors like sildenafil can affect ERK1/ERK2 phosphorylation and pulmonary artery smooth muscle proliferation.
• The workflow-focused guide "Sildenafil Citrate in Vascular and Cell Viability Assays" provides practical guidance for laboratory researchers employing PDE5 inhibitors in cell-based and vascular assays, building on the mechanistic insights into cGMP signaling pathways discussed in the reference study.

The reference study adds a new dimension, showing that even the best-characterized selective PDE5 inhibitors may exhibit off-target binding that depends on the PTM and lipidation status of target proteins—an aspect not fully addressed by traditional biochemical assays.

Protocol Parameters

• Proteoform-resolved MS analysis: Use native top-down MS workflows to directly analyze protein complexes from native membranes, avoiding detergent artifacts and preserving labile PTMs.
• PDE5 inhibitor off-target assessment: Investigate drug interactions with diverse proteoforms, especially in tissues expressing related phosphodiesterases such as PDE6, to anticipate potential side effects.
• Functional annotation of PTMs: Map lipid modifications and other PTMs using fragmentation-enabled sequencing; consider spatial localization to assess impact on membrane association and signaling.
• Experimental controls: Include proteoform-unmodified controls or use recombinant proteins lacking key PTMs to clarify the functional impact of modifications on drug binding.

Limitations and Transferability

While the native top-down MS approach offers significant advances, several limitations remain. The method currently requires specialized instrumentation and expertise, and sensitivity may be constrained for low-abundance proteoforms or rare PTMs. The study focused on retinal rod disc membranes; transferability to other tissues or more complex multicellular environments may require further optimization of sample preparation and analytical protocols. Additionally, while the approach provides direct evidence of off-target drug–proteoform interactions, translating these mechanistic insights into clinical risk assessment and therapeutic design will necessitate further validation in vivo and in patient-derived samples.

Research Support Resources

For researchers aiming to model proteoform-specific drug effects or to investigate cGMP signaling and vascular smooth muscle relaxation, high-quality reagents and robust experimental protocols are essential. Sildenafil Citrate (SKU A4321) from APExBIO, a well-characterized cGMP-specific phosphodiesterase type 5 inhibitor, offers nanomolar specificity and reliable performance in vascular, cell viability, and signal transduction assays. Its documented efficacy in modulating ERK1/ERK2 phosphorylation and supporting apoptosis regulation via cGMP signaling makes it a valuable tool for recapitulating and extending the findings of the reference study.